Also known as: Department of Commerce
President Donald Trump’s April 2, 2026 proclamation sets a 100% Section 232 tariff on certain patented pharmaceuticals and APIs from July 31, 2026. Generics, biosimilars and several specialty categories are exempt, while some companies can qualify for reduced or zero tariffs through onshoring or MFN pricing agreements.
A 6-3 Supreme Court decision rejected unlimited presidential tariff authority under IEEPA, constraining mega-tariffs while Section 232 pharmaceutical investigations and potential duties on branded medicines remain in effect.
F3 Tech will lead Maryland's proposal for a $40 million multi-user biomanufacturing facility under the federal BioMADE program, developed with the Maryland Department of Commerce to strengthen the state's biotechnology economy.
